Health Leadership and Quality of Life. 2025; 4:615
doi: 10.56294/hl2025615

ORIGINAL

A Comprehensive Study of Inflammation's Contribution to the Pathophysiology of Major Depressive Syndrome

Un Estudio Integral de la Contribución de la Inflamación a la Fisiopatología del Síndrome Depresivo Mayor

Vishakha Ganvir[1], Prashant Modi[1], Nimarpreet Kaur[2], Jagtej Singh[3], Bhavani Pentela[4], Frederick Sidney Correa[5]

[1]Parul University, Faculty of Nursing. Vadodara, India.
[2]Faculty of Medicine and Health Sciences, SGT University, Dept. of Physiology, Gurugram, India.
[3]Chitkara Centre for Research and Development, Chitkara University, Chandigarh, India.
[4]Noida Institute of Engineering and Technology Pharmacy Institute, Greater Noida, India.
[5]Centre of Research Impact and Outcome, Chitkara University, Rajpura, India.

Cite as: Ganvir V, Modi P, Kaur N, Singh J, Pentela B, Sidney Correa F. A Comprehensive Study of Inflammation's Contribution to the Pathophysiology of Major Depressive Syndrome. Health Leadership and Quality of Life. 2025; 4:615. https://doi.org/10.56294/hl2025615

Submitted: 06-06-2024 **Revised:** 09-11-2024 **Accepted:** 26-05-2025 **Published:** 27-05-2025

Editor: PhD. Prof. Neela Satheesh

Corresponding author: Vishakha Ganvir

ABSTRACT

Objective: the research aims to summaries the data demonstrating the connection between persistent low-grade inflammation and the pathophysiology of severe depression, and the effects of chronic low-grade inflammation on the immune system, neurodegeneration, and the neuroendocrine system.
Method: the research examining the connection between severe depression and inflammation. The hypothalamic-pituitary-adrenal (HPA) axis is highlighted, as are the functions of proinflammatory cytokines and the tryptophan-kynurenine pathway in neurotoxicity and oxidative stress.
Results: the HPA axis is activated, and cortisol production is enhanced in severe depression, characterized by chronic low-grade inflammation. The tryptophan-kynurenine pathway is also triggered by proinflammatory cytokines, which produce neurotoxic substances such as quinolinic acid and 3-hydroxykynurenine. Particularly in cases of late-life depression, these mechanisms lead to oxidative stress and neurodegeneration.
Conclusion: antidepressant drugs exhibit some mitigation of the immunological and endocrine alterations brought on by inflammation. Not all potent antidepressants, however, focus on these systems. To be more successful, the research advises that innovative antidepressant research should take into account medications specifically targeting the immunological, endocrine, and neurotransmitter systems.

Keywords: Chronic Inflammation; Proinflammatory Cytokines; HPA Axis; Oxidative Stress; Neurodegeneration; Tryptophan-Kynurenine Pathway; Immunomodulation; Antidepressant Therapy.

RESUMEN

Objetivo: la investigación tiene como objetivo resumir los datos que demuestran la conexión entre la inflamación crónica de bajo grado y la fisiopatología de la depresión severa, así como los efectos de esta inflamación en el sistema inmunológico, la neurodegeneración y el sistema neuroendocrino.
Método: el estudio examina la relación entre la depresión severa y la inflamación. Se destaca el eje hipotálamo-hipófiso-adrenal (HPA), así como las funciones de las citocinas proinflamatorias y la vía del triptófano-kynurenina en la neurotoxicidad y el estrés oxidativo.
Resultados: en la depresión severa, caracterizada por una inflamación crónica de bajo grado, se observa una activación del eje HPA y un aumento en la producción de cortisol. Además, las citocinas proinflamatorias

activan la vía del triptófano-kynurenina, generando sustancias neurotóxicas como el ácido quinurénico y la 3-hidroxikynurenina. Estos mecanismos provocan estrés oxidativo y neurodegeneración, especialmente en casos de depresión en la edad avanzada.
Conclusión: los fármacos antidepresivos muestran cierta capacidad para mitigar las alteraciones inmunológicas y endocrinas causadas por la inflamación. Sin embargo, no todos los antidepresivos potentes actúan sobre estos sistemas. Para mejorar la eficacia, la investigación sugiere que los estudios futuros sobre antidepresivos deberían considerar fármacos dirigidos específicamente a los sistemas inmunológico, endocrino y neurotransmisor.

Palabras clave: Inflamación Crónica; Citocinas Proinflamatorias; Eje HPA; Estrés Oxidativo; Neurodegeneración; Vía del Triptófano-Kynurenina; Inmunomodulación; Terapia Antidepresiva.

INTRODUCTION

For the past thirty years, major depressive disorder (MDD), commonly referred to as feeling depressed, has remained one of the leading causes of years lived with disability (YLD). In 2015, the World Health Organization (WHO) predicted that more than 300 million individuals worldwide live with MDD, significantly increasing the risk of killing. The administration and therapy of MDD urgently need to be boosted, especially with the expanding worldwide incidence of illness.[1]

One of the most incapacitating conditions in humanity is MDD. Neuroscience research on MDD highlights peripheral structural changes and mild neuroinflammation as potential biomarkers for early diagnosis and treatment of emotional disorders. Colleagues that found a substantial correlation between C-reactive protein (CRP) blood glucose levels and MDD in fourteen investigations provides confirmation for the significance of peripheral inflammatory procedure in psychological conditions.[2]

The most excellent crippling conditions globally, metabolic syndrome and MDD, are often associated with high comorbidities. Obesity, hyperglycemia, insulin resistance, dyslipidemia, and hypertension are some of the disorders that commonly constitute metabolic disorder, which is being defined but is known for predisposing people to heart attacks and Type 2 diabetes (T2D). The WHO projected that 650 million people obesity were prevalent globally in 2016; this figure has increased dramatically since 1975. MDD is a complicated mental condition that impairs inspiration, reasoning, and feeling.[3] MDD and also known as unipolar disorder and bipolar disorder (BD), are among the most incapacitating illnesses in the globe. There are 4,4 % of people worldwide that suffer from stress.

According to the WHO, depression is the primary contributor to suicide attempts and a major global factor in disability and "non-fatal health loss. The usual indications of MDD include melancholy, lack of enjoyment and curiosity, emotions of guilt and poor self-confidence and fatigue, disrupted rest, and difficulty concentrating. Stages of depressive and maniacal are interspersed with periods of regular emotion in bipolar disorder (BD).[4] It is generally agreed recognized immunological instability contributes significantly to the etiology of MDD in, a minimum, some individuals.

These immunological imbalances can result from childhood trauma, genetic defects, polymorphisms, persistent strain, etc. A rise in awareness of the part that a minimal amount plays in MDD's deregulated immunity.[5] The WHO has named MDD as the leading causes of impairment since it is a prevalent and occasionally deadly condition.

According to estimates, 20 % of individuals globally suffer from a significant depressive illness at some point. Approximately 50 % of depressed individuals do not react well to standard of care (SOC) therapy using depression medications, necessitating alternate or complementary therapies for this group of individuals.[6]

The most prevalent mental condition is MDD, a complicated multimodal illness. It affects over three hundred million individuals with an average yearly frequency of 4,4 % of humanity. According to the World Mental Health research, MDD is thought to have a 10-15 % lifelong incidence. MDD can be recurring or persistent in character, often accompanied by protracted episodes of melancholy and anesthesia. Significant socioeconomic effects include elevated risk of suicide, increased morbidity, disability, excess mortality, and significant financial expenses. MDD adversely impacts an individual's attitude, thoughts, and behavior, causing to experience sadness and lose passion for formerly pleasant investments.[7]

The Diagnosis and Treatment of Psychological Conditions classify MDD or anxiety, more generally, as an emotional disorder with symptoms such as persistently low feelings, exhaustion, loss of passion for routine experiences and ongoing reflections on death. Even though it has traditionally been seen as a psychological problem by communities, recent research has concentrated on the condition's neurological manifestations, especially neurological inflammation.[8]

The common mental ailment was known as MDD has a wide variety of potential outcomes, a protracted path, an extended diagnosis, a lower standard of existence, and an elevated risk of killing. Additionally,

to being a risk for suicide, the cognitive decline brought on by MDD is the responsibility of patients, their families, and society as a whole. In addition, MDD affects more than 300 million individuals globally and is the main reason individuals become disabled.[9]

MDD impairs performance throughout adolescence and results in several physical and mental issues later in permanently. MDD's precise pathogenesis is yet not entirely known. The disruption in monoamine neural communication remains the subject of most investigation since modern depressive therapies concentrate on restoring typical amounts of monoamines, such as serotonin and the hormone. Depressive illness, however, is assumed to be accompanied by more intricate systems. The etiology of MDD includes alterations in the immune system in addition to stress-induced neurological inflammation and related changes in the structure of the mind.[10]

The research explored the neurobiological changes linked to Post-Traumatic Stress Disorder (PTSD) and MDD.[11] It also emphasizes potential overlaps and distinctions among these diseases to support the hypothesis that these illnesses have common physiology. It underlines the significant experimental findings from the deceased have influenced in neuroscience knowledge, impacting the cause and treatment of MDD or PTSD. The research demonstrated the primary infectious predictions of MDD, starting with the earliest ones depending on the monoaminergic and neurotrophic ideas, moving on to the later inflammatory/immune, glutamatergic, GABAergic, and neurological growth, and hormonal clarifications, and ending with the majority of current data indicate a function for fatty acids and the gut microbiome.[12] A discussion of proven treatment methods for MDD is also regarding their biological consequences.

The research looked at the changed metabolism in several bio-samples from depressed and MDD client models.[13] Additionally, compiled the compounds linked to depression therapy outcomes. The mental illness known as MDD is widespread, incapacitating, and has an elevated incidence. While the primary causes of MDD are unknown, several social, biological, and psychological elements are linked to the disease's etiology. The current meta-analytic and systemic research goal examined how Selective Serotonin Reuptake Inhibitor (SSRI) therapy affects the levels of several indicators of inflammation in the peripheral blood samples of MDD patients.[14] In MDD, systemic inflammatory marker levels are increased. The concentrations of inflammation-related indicators are impacted by SSRI in individuals having MDD; however, research has shown mixed results.

The research on the connection between "immune-related genes (IRGs)" and immunological infiltrates in MDD.[15] The immune system and the pathogenesis of MDD are often linked.148 MDD sufferers' expressions were taken from two groups, and used the R applications limma function to define IRGs that were differently elevated thoroughly. The strongest IRGs were then determined using LASSO and multivariate logistic regression research. The link between MDD immunological impacts and IRGs was then examined.

The research used a longitudinal, case-control approach to measure the blood levels of complement C1q in MDD patients.[16] Also evaluated in individuals with MDD were the relationships links cholesterol levels, irritation, and complementing factor C1q. Inflammation, synaptic pruning, and apoptosis of the physiological reactions in which the supplements system was engaged. It is unclear, nevertheless, whether peripheral complement C1q levels differ in people with MDD.

The research examines the relationship between neurological connective architecture, cognitive function, and polymorphic associated with T2D in 434 non-diabetic individuals with MDD and 539 healthy control people.[17] It was well established that "type 2 diabetes mellitus (T2D)" and MDD exhibit medical association and a typical genome. However, limited has been learned regarding the processes that regulate genetic susceptibility of T2D can influence the functioning of the brain and, where these consequences can be related to the operation of MDD. In addition to having similar inheritance, both medical conditions appear connected with modifications in cerebral connective tissue and weakened memory.

The research examined one of the fundamental foundations of wellness, affecting several biological processes in the nervous system and the body as a whole.[18] Lack of nutrition and MDD appear to be correlated in both directions, and depressed people frequently miss some essential nutrients and have abnormal diet habits for eating. As a consequence, Nutritional changes are among the majority of effective ones. Strategies to investigate MDD since a particular subset of vitamins, products, or nutritional products have been researched.

The article investigated to give an improved understanding of the pathophysiology of MDD by demonstrating how these many signaling pathways and systems could combine.[19] The various paths or chemical components be examined for connections to synapses' neural communication, keeping in mind that the sequence of neuronal firing is the most accurate physiological depiction of mood, emotion, and conscience can imagine.

The link between persistent low-grade inflammation and the pathophysiology of severe depression is supported by evidence, highlighting the effect of chronic inflammation on the immune system, neurodegeneration, and neuroendocrine function.

https://doi.org/10.56294/hl2025615

METHOD

Inflammatory Markers and Measurements

These parts describe the method for assess the occurrence and degree of inflammation in participants, focus on inflammatory biomarkers. These biomarkers are naturally substance released by immune cells during inflammation, and serve as indicators of systemic inflammation. CRP is a famous acute-phase protein that rises in reaction to inflammation, while IL-6 and TNF-α are proinflammatory cytokines that play key roles in the immune reaction. The choice of biomarkers depends on the investigate objectives for example, CRP for ordinary inflammation and IL-6 or TNF-α for exact neuro inflammatory pathways. These biomarkers are usually calculated using blood samples. General approach includes Enzyme-Linked Immunosorbent Assay (ELISA), which quantifies the stage of these proteins by using antibodies exact to the target protein, or Polymerase Chain Reaction (PCR), which can measure gene appearance associated to inflammation. The accuracy of these tests is critical. The sensitivity refers to the test's capability to acceptably recognize the occurrence of inflammation, while specificity refers to how well the test distinguishes among inflammation and other environment. Standardized protocol must be followed to confirm constancy across all samples, and constant measurements can be taken to improve reliability.

Neuroendocrine and Immune System Evaluation

This section explores the intricate association between chronic inflammation, the HPA axis, and the immune system in the increase of depression. Persistent inflammation can dysregulate the HPA axis, which govern the body's stress response, leading to chronic activation and elevated cortisol levels—a key characteristic of severe depression. Cortisol levels, often exact in blood or saliva sample at a variety of period of the day to evaluate diurnal patterns, are frequently linked to despair and prolonged stress exposure. Additionally, proinflammatory cytokines such as IL-1, IL-6, and TNF-α play a critical role in the immune response to inflammation. These cytokines contribute to neuroinflammation and mood disturbances, further influencing the pathophysiology of depression. These cytokines can be measured through ELISA, immunoassays, or flow cytometry. This part evaluate how chronic low-grade inflammation leads to change in immune cell activity, such as enlarged immune activation or dysfunction of regulatory pathways that could contribute to depressive symptoms. Table 1 demonstrates the dysregulated cortisol and stress response in depressive disorders. Researcher's strength assesses immune cell profiles (e.g., T-cell subsets) to gain insight into the immune dysregulation linked to depression.

Table 1. HPA Axis Dysregulation: A Key Contributor to Depression.

Category	Key Factors	Effects on Depression	Measurement Methods
HPA Axis Dysregulation	Chronic stress, elevated cortisol levels	Increased vulnerability to depression	Blood/saliva cortisol assays (morning/evening)
Cortisol Dysregulation	High or dysregulated levels	Impaired stress response, mood disturbances	ELISA, immunoassays
Proinflammatory Cytokines	IL-1, IL-6, TNF-α	Induce neuroinflammation, alter neurotransmission	ELISA, flow cytometry, immunoassays
Immune System Activation	Overactive or dysregulated immune cells	Increased inflammatory response, mood changes	Immune profiling (T-cell subsets)
Regulatory Pathway Dysfunction	Impaired feedback mechanisms	Sustained inflammation, depressive symptoms	Flow cytometry, immunophenotyping

Tryptophan-Kynurenine Pathway Analysis

The tryptophan-kynurenine pathway the stage a crucial role in linking inflammation to neurotoxicity and oxidative stress, both of which contribute to depression. Inflammatory processes drive the conversion of tryptophan, a serotonin precursor, into kynurenine, leading to dysregulation of this pathway in individuals with depression. Researchers investigate key metabolites within this pathway, such as kynurenine, 3-hydroxykynurenine, and quinolinic acid. Kynurenine levels are typically assessed by HPLC (high-performance liquid chromatography), while mass spectrometry is employed to measure 3-hydroxykynurenine and quinolinic acid. Quinolinic acid, a neurotoxin, can damage neurons and contribute to neurodegeneration in depression. These metabolites because can indicate the degree of neurotoxicity, particularly in the context of neurodegenerative diseases like Alzheimer's, which often co-occur with depression. The dysregulation of this pathway lead to reduced serotonin production (linked to mood disorders) and the accumulation of neurotoxic substances, which could explain some of the cognitive and emotional symptom of depression. This section examines the start of the tryptophan-kynurenine pathway in depression and its role in disease pathology. As demonstrate in Figure 1, the kynurenine pathway serves as the primary route for tryptophan (Trp) catabolism, initiate with its change into N-formyl kynurenine (NFK). This procedure is catalyzed by tryptophan 2,3-dioxygenase (TDO) in the liver or by indoleamine 2,3-dioxygenase (IDO1, IDO2) in extrahepatic tissues.

https://doi.org/10.56294/hl2025615



Figure 1. Critical steps of the kynurenine pathway of Trp degradation.

IDO1 possesses superior catalytic activity, while IDO2 plays a regulatory role in modulate its function. Arylformamidase (AFMID) then processes NFK to produce kynurenine (KYN), a crucial intermediate. KYN can be further changed into kynurenic acid (KYNA), anthranilic acid (AA), or 3-hydroxykynurenine (3HK) through the actions of KYAT, KYNU, or KMO, respectively. These metabolites undergo additional transformations, leading to the formation of 3-hydroxyanthranilic acid (3HAA), picolinic acid (PIC), and quinolinic acid (QUIN), ultimately causal to the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a vital coenzyme for energy metabolism and cellular processes.

Neurotoxicity and Oxidative Stress Assessment

Neurotoxicity and oxidative force are central to the neurodegenerative feature of depression, where inflammatory pathways contribute to cellular damage and neuronal death. Oxidative pressure marker measure biomarkers such as MDA (malondialdehyde), a producer of lipid peroxidation, which serves as an indicator of oxidative damage to cell membranes. Other markers include SOD (superoxide dismutase), an enzyme that support protect cells from oxidative damage, and glutathione, an antioxidant that combats free radicals. The increase of neurotoxic substance like quinolinic acid is assess to understand the cellular damage that occurs in the brain due to inflammation and oxidative anxiety. Advanced methods like MRI (Magnetic Resonance Imaging) or PET (Positron Emission Tomography) can be employed to observe any structural or useful modify in the brain associated with this method. Table 2 demonstrates measuring cellular and neural damage biomarkers and their significance. This section explains how the expansion of oxidative stress leads to neuronal damage, which is connected with the cognitive and emotional symptom seen in severe depression. It ties into the broader question of how inflammatory process supply to the brain's degeneration in depression.

Antidepressant and Anti-inflammatory Treatment

The potential therapeutic impacts of antidepressants and anti-inflammatory medications in modulate the inflammatory process that contribute to depression. The section describes the antidepressants (e.g., SSRIs, SNRIs) and anti-inflammatory drugs (e.g., NSAIDs, corticosteroids) utilized in the research. SSRIs and SNRIs target neurotransmitter imbalances, while NSAIDs and corticosteroids can reduce inflammation. The research explains how participant were treated, include the dosage, duration of treatment, and whether the medications were administered alone or in mixture with other therapies (e.g., psychotherapy). The section explores how these medications are believed to modulate the immune response, reduce proinflammatory cytokines, or restore balance to the HPA axis. It also discusses whether antidepressants can ultimately address inflammation-induced neurotoxicity by normalize neurotransmitter level. A clearer understanding of the methodologies used to assess various biological systems, inflammation-related biomarkers, and treatments in the research of depression and inflammation. The section focuses on how each approach provides insight into the inflammatory mechanisms involved in depression and how treatments can target these processes to improve clinical outcomes. Figure 2 illustrates the potential anti-inflammatory mechanisms of antidepressants. Selective serotonin reuptake inhibitors (SSRIs), which elevate serotonin levels, can achieve their anti-inflammatory effects through cAMP-mediated pathways. Serotonin (5-HT) enhances intracellular cAMP levels by activating 5-HT receptors associated with G protein-stimulated adenylyl cyclase. This activation subsequently suppresses cytokine expression by inhibiting the protein kinase A (PKA) pathway.

https://doi.org/10.56294/hl2025615

Table 2. Key Biomarkers in Oxidative Stress and Neurotoxicity.

Category	Biomarkers/Indicators	Function/Significance	Measurement Method
Oxidative Stress Markers	Malondialdehyde (MDA)	Indicator of lipid peroxidation and oxidative damage to cell membranes	Thiobarbituric Acid Reactive Substances (TBARS) assay
	Superoxide Dismutase (SOD)	Antioxidant enzyme that protects cells from oxidative damage	Spectrophotometric assay
	Glutathione (GSH)	Antioxidant that combats free radicals	High-Performance Liquid Chromatography (HPLC)
Neurotoxicity Markers	Quinolinic Acid	Neurotoxic metabolite contributing to cellular damage in the brain	Liquid Chromatography-Mass Spectrometry (LC-MS)
	MRI/PET Scans	Observes structural and functional changes in the brain	Magnetic Resonance Imaging (MRI) / Positron Emission Tomography (PET)
Link to Depression	Oxidative Stress and Neurotoxicity	Contributes to neuronal damage, cognitive, and emotional symptoms in depression	Correlation with clinical depression scales (e.g., HAMD, BDI)



Figure 2. Potential Anti-Inflammatory Mechanisms of Action of Antidepressants.

RESULTS

Inflammation plays a crucial role in the pathophysiology of Major Depressive Syndrome (MDD) by altering neuroimmune interactions, increasing pro-inflammatory cytokines (e.g., IL-6, TNF-α), and disrupting neurotransmitter systems. Chronic inflammation can lead to HPA axis dysregulation, oxidative stress, and neurodegeneration, contributing to depressive symptoms. Understanding these mechanisms can help develop targeted anti-inflammatory treatments for MDD.

Interferon-Alpha Treatment and Major Depressive Disorder: Clinical Observations and Biochemical Correlations

Clinical investigations have shown that between 16 % and 46 % of IFN-treated individuals experience the onset of MDD. Patients taking IFN- for aggressive melanoma in a double-blind, placebo-controlled research experienced depression within 12 weeks of treatment. (Figure 3and table 3) patients were observed to have severe depressed symptoms that necessitated stopping their therapy.



Figure 3. The Tryptophan-Kynurenine Route, Which Connects Discomfort, Swelling, And Sadness.

https://doi.org/10.56294/hl2025615

Table 3. Concentrations of interleukin 6 (IL-6) in patients receiving interferon-alpha (IFN-alpha) compared to those who do not develop MDD.

IL6 concentrations (pg/ml)-square root transformed	No MDD	Developed MDD
0	0,9	1,1
1	1	1,6
2	0,8	1,6
3	0,8	2,3
4	0,8	-

Interleukin-6 (IL-6) Levels in Patients with and Without Major Depressive Disorder (MDD)

The results indicate a significant increase in IL-6 levels among patients who developed MDD, while individuals without MDD maintain relatively stable levels. This indicates that inflammation can contribute to the development and progression of depression.IL-6 is a pro-inflammatory cytokine involved in immune response regulation. Figure 4 illustrates the progression of IL-6 levels (square root transformed) over multiple time points, comparing individuals who developed MDD with those who did not. Previous research has linked elevated IL-6 levels with various psychiatric disorders, particularly depression. The research supports the hypothesis that chronic inflammation plays a role in the development of MDD. Elevated IL-6 levels can serve as an early biomarker, aiding in the identification of at-risk individuals before clinical symptoms appear.



Figure 4. IL-6 Levels in patients with and Without MDD.

The implications of these findings extend to potential therapeutic strategies. Anti-inflammatory treatments, such as cytokine inhibitors or lifestyle interventions targeting inflammation, can prove beneficial in managing or preventing MDD. Additionally, routine monitoring of inflammatory markers in individuals with high psychological stress or a predisposition to depression could enhance early detection and intervention strategies. Further research is needed to explore the causal mechanisms and the potential of IL-6 as a predictive tool for MDD.

Anti-Inflammatory Medications Are Thus Possible Antidepressants since Prostaglandins Are a Source of Inflammation in Depression

Prostaglandins, lipid substances generated from arachidonic acid, are known to exacerbate inflammation in several disorders, including depression. Ithave been linked to the inflammatory response. Prostaglandins could exacerbate inflammation by triggering the production of proinflammatory cytokines, raising blood vessel permeability, and sensitizing pain receptors. To lessen inflammation and discomfort, “nonsteroidal anti-inflammatory medications (NSAIDs)” prevent the synthesis of prostaglandins. NSAIDs help reduce inflammation and its accompanying symptoms by inhibiting the activity of “cyclooxygenases (COX),” which are involved in manufacturing prostaglandins.

Anti-inflammatory medications, especially NSAIDs, have the potential to be used as supplementary therapy for depression, given the link between inflammation and depression. Specific NSAIDs, such as celecoxib, could have antidepressant benefits, according to detailed research, mainly when used with conventional antidepressants. Anti-inflammatory medications’ capacity to modify the inflammatory response and impact the neurochemical pathways involved in mood regulation can be linked to their possible antidepressant effects. These medications could aid in regaining regular brain function and easing depression symptoms by lowering inflammation. It’s crucial to remember that, despite the data pointing to a connection between inflammation and depression, research on the particular function of prostaglandins in the development of depression is ongoing. The complex condition of depression has many underlying causes, and not all instances of depression are linked to inflammation or improvement with anti-inflammatory treatments. The usefulness and safety

of anti-inflammatory medications for treating depression must be further demonstrated, and research into their usage as antidepressants is currently underway. For an accurate assessment and advice on how to cure depression, it's crucial to speak with a healthcare expert. Offer personalized recommendations based on individual needs and situations. The research also discovered that MDD development after IFN-therapy was predicted by greater preparation IL-6 levels (figure 5 and table 4).



Figure 5. Prospective MDD is predicted by baseline interleukin 6 (IL-6) phases.

Table 4. Developing MDD is predicted by interleukin 6 (IL-6) pretreatment stages.

Days after starting interferon-alpha	High IL-6	Low IL-6
0	100`	100
20	98	90
40	82	84
60	73	80
80	70	80
100	60	80
120	60	80

Impact of Anti-Inflammatory Treatment on Depression Symptoms

The results show a clear reduction in depression severity for patients receiving anti-inflammatory treatment, while the no-treatment group exhibits only a slight decline in symptoms. Both groups have similar depression severity scores. Figure 6 depicts the impact of anti-inflammatory treatment on depression symptom severity over a 10-week period. However, as the treatment progresses, the anti-inflammatory group shows a consistent and steep decline in symptoms, reaching significantly lower levels by week 10. In contrast, the no-treatment group exhibits only a gradual reduction in symptom severity.



Figure 6. Impact of Anti-Inflammatory Treatment on Depression.

These findings suggest that inflammation can contribute to depression, and targeting inflammation could be a potential strategy for alleviating depressive symptoms. Anti-inflammatory treatments, such as cytokine inhibitors or lifestyle interventions like dietary changes and exercise, can serve as effective adjunct therapies

for individuals with depression. Further investigation is necessary to understand the mechanisms behind this relationship and establish optimal treatment protocols. Incorporating anti-inflammatory approaches into mental health care can enhance outcomes for individuals with treatment-resistant depression.

Moving Towards an Integrated Understanding of How Medications Work

A challenging and developing area of research is figuring out how antidepressants work. Even the precise processes need to be completely understood, a comprehensive analysis of their activities could provide light on how these drugs work to treat certain conditions. The following are some essential elements that help to get an integrated understanding.

Numerous antidepressants, including SSRIs and TCAs, focus primarily on regulating the brain's neurotransmitter systems. By preventing their absorption or promoting their release, boost the availability of neurotransmitters, including serotonin, norepinephrine, and dopamine. Antidepressants could affect the cognitive processes, emotional processing, and mood regulation linked to depression via changing neurotransmitter levels.

Synaptic connection and neuroplasticity It have been discovered that antidepressants support neuroplasticity, the brain's capacity to modify and reorganize its structure and function. It could promote the formation of new neurons (neurogenesis) and enhance the growth and stability of new neural connections (synaptogenesis) in certain brain areas, such as the hippocampus. The lasting benefits of antidepressant treatment can result from neuroplastic changes, which are believed to contribute to the sustained effects of therapy.

Regulation of the stress response Depression is associated with prolonged stress and imbalance of the HPA axis, a key component of the stress response system. The function of the HPA axis can be reinstated to its usual state, potentially reducing the secretion of cortisol and other stress-related hormones. Antidepressants could aid in mood regulation and lessen the damaging effects of stress on the brain by modifying the stress response. Modulation of inflammation there is mounting evidence that depression and inflammation are related. By lowering the generation of proinflammatory cytokines and regulating immunological responses, antidepressants, in particular certain SSRIs, have been demonstrated to have anti-inflammatory impacts. Antidepressants' capacity to inhibit inflammation can play a role in the therapeutic effects of these drugs. Neurocircuitry and operational interconnectivity changes in brain connectivity and functional networks are associated with depression. It has been shown that pharmaceuticals affect the functional connectivity of specific brain circuits, including the default mode network and areas involved in emotional processing. Depression medications can aid in mood regulation and reduce feelings of depression by altering brain circuitry and reestablishing functional connections.

Antidepressants can influence epigenetic processes, which regulate gene activity without changing the fundamental DNA sequence. It could change the way that genes related to inflammation, neuroplasticity, and stress response function. These epigenetic alterations could influence the long-lasting effects of antidepressant medication. Remember that the processes discussed here are interrelated and that can have an impact on one another. According to an integrated theory of antidepressant functions, these medications work by altering neurotransmitter levels, neuroplasticity, stress levels, inflammation levels, neurocircuitry, and epigenetics. However, considering the particular drug and personal traits, these systems' exact involvement and combinations can change.

CONCLUSIONS

Antidepressants can partially mitigate the immunological and endocrine changes caused by chronic low-grade inflammation in severe depression. However, not all antidepressants target these systems. Severe depression is closely linked to chronic low-grade inflammation, which significantly impacts the immune, neuroendocrine, and neurodegenerative systems. The activation of the HPA axis and the tryptophan-kynurenine pathway results in increased cortisol production and neurotoxic effects, contributing to oxidative stress and neuronal damage, particularly in late-life depression. The drawbacks, there is enough data to infer that the prolonged, moderate activation theory helps a thorough understanding of the psychopathology of depression and how pharmaceuticals could ease the indications. In addition, the idea suggests avenues for creating novel depressive formulations, which should increase their effectiveness. Future research should focus on developing treatments that specifically address immune, endocrine, and neurotransmitter imbalances for more effective therapeutic outcomes.

REFERENCES

1. Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, Karagiannis TC. Thecellular and molecular basisofmajordepressivedisorder: towards a unifiedmodelforunderstandingclinicaldepression. Molecular biologyreports. 2020 Jan;47:753-70.

2. Opel N, Cearns M, Clark S, Toben C, Grotegerd D, Heindel W, Kugel H, Teuber A, Minnerup H, Berger K, Dannlowski U. Large-scaleevidenceforanassociationbetweenlow-grade peripheralinflammation and

brainstructuralalterations in majordepression in theBiDirectstudy. JournalofPsychiatry and Neuroscience. 2019 Nov 1;44(6):423-31.

3. Chan KL, Cathomas F, Russo SJ. Central and peripheralinflammation link metabolicsyndrome and majordepressivedisorder. Physiology. 2019 Mar 1;34(2):123-33.

4. Knuesel T, Mohajeri MH. The role ofthegutmicrobiota in thedevelopment and progressionofmajordepressive and bipolar disorder. Nutrients. 2021 Dec 23;14(1):37.

5. Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Müller N, Drexhage HA. Low-grade inflammation as a predictor ofantidepressant and anti-inflammatorytherapy response in MDD patients: a systematicreviewoftheliterature in combinationwithananalysisof experimental data collected in the EU-MOODINFLAME consortium. Frontiers in psychiatry. 2019 Jul 9;10:458.

6. Petralia MC, Mazzon E, Fagone P, Basile MS, Lenzo V, Quattropani MC, Bendtzen K, Nicoletti F. PathogeniccontributionoftheMacrophagemigrationinhibitory factor familytomajordepressivedisorder and emergingtailoredtherapeuticapproaches. Journalofaffectivedisorders. 2020 Feb 15;263:15-24.

7. Kamran M, Bibi F, ur. Rehman A, Morris DW. Majordepressivedisorder: existinghypothesesaboutpathophysiologicalmechanisms and new geneticfindings. Genes. 2022 Apr 6;13(4):646.

8. Tran AA, De Smet M, Grant GD, Khoo TK, Pountney DL. Investigatingtheconvergentmechanismsbetweenmajordepressivedisorder and Parkinson'sdisease. ComplexPsychiatry. 2021 Feb 16;6(3-4):47-61.

9. Ignácio ZM, da Silva RS, Plissari ME, Quevedo J, Réus GZ. Physicalexercise and neuroinflammation in majordepressivedisorder. Molecular neurobiology. 2019 Dec;56(12):8323-35.

10. Öztürk M, YalınSapmaz Ş, Kandemir H, Taneli F, Aydemir Ö. The role ofthekynureninepathway and quinolinicacid in adolescentmajordepressivedisorder. International journalofclinicalpractice. 2021 Apr;75(4):e13739.

11. Ploski JE, Vaidya VA. Theneurocircuitryof PTSD and majordepression: insightsintooverlapping and distinctcircuitdysfunction-a tribute to Ron Duman. Biologicalpsychiatry. 2021 Apr 24;90(2):109.

12. Maffioletti E, Minelli A, Tardito D, Gennarelli M. Blues in thebrain and beyond: molecular basesofmajordepressivedisorder and relativepharmacological and non-pharmacologicaltreatments. Genes. 2020 Sep 18;11(9):1089.

13. Duan J, Xie P. Thepotentialformetabolomics in thestudy and treatmentofmajordepressivedisorder and relatedconditions. ExpertReviewofProteomics. 2020 Apr 2;17(4):309-22.

14. Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. EffectsofSSRIsonperipheralinflammatorymarkers in patientswithmajordepressivedisorder: a systematicreview and meta-analysis. Brain, behavior, and immunity. 2019 Jul 1;79:24-38.

15. Ning L, Yang Z, Chen J, Hu Z, Jiang W, Guo L, Xu Y, Li H, Xu F, Deng D. A novel 4 immune-related genes as diagnosticmarkers and correlatedwithimmuneinfiltrates in majordepressivedisorder. BMC immunology. 2022 Feb 13;23(1):6.

16. Yao Q, Li Y. Increasedserumlevelsofcomplement C1q in majordepressivedisorder. JournalofPsychosomaticResearch. 2020 Jun 1;133:110105.

17. Repple J, König A, de Lange SC, Opel N, Redlich R, Meinert S, Grotegerd D, Mauritz M, Hahn T, Borgers T, Leehr EJ. Associationbetweengeneticriskfortype 2 diabetes and structuralbrainconnectivity in majordepressivedisorder. BiologicalPsychiatry: CognitiveNeuroscience and Neuroimaging. 2022 Mar 1;7(3):333-40.

18. Ortega MA, Fraile-Martínez Ó, García-Montero C, Alvarez-Mon MA, Lahera G, Monserrat J, Llavero-Valero M, Gutiérrez-Rojas L, Molina R, Rodríguez-Jimenez R, Quintero J. Biological role ofnutrients, food

and dietarypatterns in theprevention and clinicalmanagementofmajordepressivedisorder. Nutrients. 2022 Jul 28;14(15):3099.

19. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathwaysofmajordepressivedisorder converge onthesynapse. Molecular Psychiatry. 2023 Jan;28(1):284-97.

FINANCING

None.

CONFLICT OF INTERESTS

None.

AUTHORS CONTRIBUTION

Conceptualization: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Data curation: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Formal analysis: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Research: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Methodology: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Writing – original draft: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.

Writing – review & editing: Vishakha Ganvir, Prashant Modi, Nimarpreet Kaur, Jagtej Singh, Bhavani Pentela, Frederick Sidney Correa.